Abstract:
The present invention relates to methods of producing an antigenic response in which an antigen is contacted to an antigen-presenting cell, wherein the improvement comprises contacting the antigen-presenting cell with an A1 adenosine receptor activating agent in an amount sufficient to increase the antigenic response of the antigen-presenting cell to the antigen. The present invention further provides methods, compositions, combination therapies, imaging techniques, and diagnostic kits that may improve the diagnosis, prognosis, and/or survival of cancer patients, pathogen-infected patients, and infectious or non-infectious immune-deficient patients.
Abstract:
The present invention relates to methods of producing an antigenic response in which an antigen is contacted to an antigen-presenting cell, wherein the improvement comprises contacting the antigen-presenting cell with an A1 adenosine receptor activating agent in an amount sufficient to increase the antigenic response of the antigen-presenting cell to the antigen. The presen t invention further provides methods, compositions, combination therapies, imaging techniques, and diagnostic kits that may improve the diagnosis, prognosis, and/or survival of cancer patients, pathogen-infected patients, a nd infectious or non-infectious immune-deficient patients.
Abstract:
The present invention relates to the methods of use for measurement of lipopolysaccharide (LPS) and methods of use for diagnosis of sepsis and LPS-related conditions. Specifically the present invention relates to a time resolved fluorescence (TRF) based assay for the measurement of LPS and methods of use for the measurement of LPS to diagnose sepsis, Gram-negative bacterial infections, and LPS-related conditions.
Abstract:
A1 adenosine receptor antagonists and P2X receptor antagonists are useful in the treatments of disorders of the immune system, which include HIV infectio n, AIDS, and adenosine deaminase deficiency-dependent severe immunodeficiency disease (ADA SCID).
Abstract:
Glycolipids are useful for enhancing the affinity of A1 adenosine receptor ligands for the A1 adenosine receptor. Glycolipids are accordingly useful in diagnostic and therapeutic methods that require the delivery or administrati on of A1 adenosine ligands.
Abstract:
The present invention relates to the methods of use for measurement of lipopolysaccharide (LPS) and methods of use for diagnosis of sepsis and LPS-related conditions. Specifically the present invention relates to a time resolved fluorescence (TRF) based assay for the measurement of LPS and methods of use for the measurement of LPS to diagnose sepsis, Gram-negative bacterial infections, and LPS-related conditions.